Search Results
3 Insights from a Clinical Trial Patient
The road to finding new and better cancer treatments often includes an important step: clinical trials. For patients with hard-to-treat diseases, these studies can be superhighways to the right treatment. A clinical trial can tell oncologists whether a new treatment works, how certain cancer types affect the body, and more.
Champions in myeloma research: A conversation with Urvi A. Shah, M.D. M.S.
March is Myeloma Awareness Month, and it’s also Women’s History Month. So what better time to spotlight LLS-funded women scientists who are driving discovery for myeloma patients.
In this first of my two-part series on myeloma researchers, I sat down with Urvi A. Shah, MD, MS, an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center.
A phase 1/2 study of DR-01, an anti-CD94 monoclonal antibody, in patients with large granular lymphocytic leukemia or cytotoxic lymphomas
In November 2022, LLS made an equity investment in Dren Bio to "Support Clinical Development of the DR-01 Program for Rare Leukemia & Lymphoma Indications Including Large Granular Lymphocyte Leukemia (LGLL) and Cytotoxic Lymphomas."Mechlorethamine
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Vinblastine
Vinblastine is an FDA-approved chemotherapy agent that is used to treat people who have acute leukemia. It is sometimes used to treat other types of cancer including lymphoma.
Vorinostat
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Bendamustine hydrochloride
Bendamustine hydrochloride is FDA approved to treat people who have:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Denileukin diftitox-cxdl
Denileukin diftitox-cxdl is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
New Study Shows 9/11 Responders Have Higher Rates of Leukemia
All 9/11 responders put their own lives at risk to save others from the events that occurred at the World Trade Center (WTC) on September 11, 2001, in New York City. Since then, several studies have shown elevated rates of cancers such as multiple myeloma, prostate cancer and thyroid cancer among first responders and those who worked nearby.
Support at Your Fingertips: Try a Discussion Board
Having cancer can be a lonely experience, and it’s not always so easy to find others with a similar diagnosis. Even if you could, you might not always want to talk about everything face to face.
Sometimes an online discussion board is just what you need.
Predictors of response to therapy in A051902, a US Intergroup study of duvelisib+CHO(E)P vs CC-486+CHO(E)P vs CHO(E)P in peripheral T-cell lymphoma
We are evaluating if adding duvelisib or azacitidine to standard chemotherapy increases the complete remission rate compared to chemotherapy alone in peripheral T-cell lymphoma. We believe that adding novel agents to chemotherapy will most benefit lymphomas with a T-follicular helper phenotype. We will also study if tests for lymphoma cells in the blood can predict outcomes. We hope these novel therapies will cure more patients and we can identify who is most likely to benefit from them.Doxorubicin
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Etoposide
Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.
Methotrexate
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Bexarotene
Bexarotene is FDA approved to treat people who have skin problems arising from cutaneous T-cell lymphoma (CTCL) in patients who are refractory for at least one prior systemic therapy. It may be used after other drugs have been tried and the tumor is still a problem.
One More 'Ologist'
After staring down Stage IV non-Hodgkin lymphoma in 2016, I AM HERE, and I am grateful beyond measure. However, I am learning that the treatments that saved my life came at a high cost, and that in its own way survivorship is the hardest part of what I and my family now call, “the adventure.” 'The adventure' is certainly never what we imagined it would be.